Cargando…

CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis

BACKGROUND: CGRP monoclonal antibody (mAb) is a promising preventive treatment for episodic migraine and has been approved by US FDA recently. But the treatments for chronic migraine are rare. Therefore, we performed meta‐analysis to assess the efficacy and safety of CGRP mAbs in preventing chronic...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Lin, Liu, Yao, Xiong, Hai, Hong, Peiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379644/
https://www.ncbi.nlm.nih.gov/pubmed/30656853
http://dx.doi.org/10.1002/brb3.1215
_version_ 1783396134252707840
author Han, Lin
Liu, Yao
Xiong, Hai
Hong, Peiwei
author_facet Han, Lin
Liu, Yao
Xiong, Hai
Hong, Peiwei
author_sort Han, Lin
collection PubMed
description BACKGROUND: CGRP monoclonal antibody (mAb) is a promising preventive treatment for episodic migraine and has been approved by US FDA recently. But the treatments for chronic migraine are rare. Therefore, we performed meta‐analysis to assess the efficacy and safety of CGRP mAbs in preventing chronic migraine. METHODS: Database including Cochrane Library and PubMed were systematically searched for randomized controlled trials (RCTs) which are about CGRP mAb in preventing treatment of chronic migraine. Evaluating the bias and quality of RCTs was carried out according to the Cochrane collaboration's tool for assessing risk of bias. The data analysis was carried out by reviewer manager 5.2. RESULTS: Totally, 6 articles enrolled in the present meta‐analysis, including 4 independent clinical trials and 3,166 patients. After pooled analysis, it indicated that CGRP mAb improved 50% responder rate (OR = 2.42, 95% CI = [2.04, 2.87], I (2) = 0%, p < 0.00001) and 75% responder rate (OR = 1.95, 95% CI = [1.30, 2.91], I (2) = 0%, p = 0.001), as compared with placebo. And there was no difference in incidence of adverse events between CGRP mAb group and placebo group except incidence of injection site discomfort. CONCLUSIONS: CGRP mAb is an effective and safety preventive treatment for chronic migraine.
format Online
Article
Text
id pubmed-6379644
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-63796442019-02-28 CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis Han, Lin Liu, Yao Xiong, Hai Hong, Peiwei Brain Behav Original Research BACKGROUND: CGRP monoclonal antibody (mAb) is a promising preventive treatment for episodic migraine and has been approved by US FDA recently. But the treatments for chronic migraine are rare. Therefore, we performed meta‐analysis to assess the efficacy and safety of CGRP mAbs in preventing chronic migraine. METHODS: Database including Cochrane Library and PubMed were systematically searched for randomized controlled trials (RCTs) which are about CGRP mAb in preventing treatment of chronic migraine. Evaluating the bias and quality of RCTs was carried out according to the Cochrane collaboration's tool for assessing risk of bias. The data analysis was carried out by reviewer manager 5.2. RESULTS: Totally, 6 articles enrolled in the present meta‐analysis, including 4 independent clinical trials and 3,166 patients. After pooled analysis, it indicated that CGRP mAb improved 50% responder rate (OR = 2.42, 95% CI = [2.04, 2.87], I (2) = 0%, p < 0.00001) and 75% responder rate (OR = 1.95, 95% CI = [1.30, 2.91], I (2) = 0%, p = 0.001), as compared with placebo. And there was no difference in incidence of adverse events between CGRP mAb group and placebo group except incidence of injection site discomfort. CONCLUSIONS: CGRP mAb is an effective and safety preventive treatment for chronic migraine. John Wiley and Sons Inc. 2019-01-18 /pmc/articles/PMC6379644/ /pubmed/30656853 http://dx.doi.org/10.1002/brb3.1215 Text en © 2019 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Han, Lin
Liu, Yao
Xiong, Hai
Hong, Peiwei
CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
title CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
title_full CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
title_fullStr CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
title_full_unstemmed CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
title_short CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
title_sort cgrp monoclonal antibody for preventive treatment of chronic migraine: an update of meta‐analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379644/
https://www.ncbi.nlm.nih.gov/pubmed/30656853
http://dx.doi.org/10.1002/brb3.1215
work_keys_str_mv AT hanlin cgrpmonoclonalantibodyforpreventivetreatmentofchronicmigraineanupdateofmetaanalysis
AT liuyao cgrpmonoclonalantibodyforpreventivetreatmentofchronicmigraineanupdateofmetaanalysis
AT xionghai cgrpmonoclonalantibodyforpreventivetreatmentofchronicmigraineanupdateofmetaanalysis
AT hongpeiwei cgrpmonoclonalantibodyforpreventivetreatmentofchronicmigraineanupdateofmetaanalysis